Attovia's ATTO-1310 Holds 82% Itch Response at Week 12 After Single Dose
ATTO sits 16% above its 52-week low of $12.94.
Summary
Attovia reported 12-week topline Phase 1b data for ATTO-1310, extending the preliminary Week 4 findings disclosed with Q2 results in September. In chronic pruritus, 82% of treated patients hit PP-NRS4 versus 22% on pooled placebo (p<0.01), and 47% reached itch-free or nearly itch-free status versus 0% on placebo. A single subcutaneous dose kept circulating IL-31 suppressed roughly 95% through Week 12, which is the basis for the company's quarterly-dosing thesis. The high-itch atopic dermatitis arm was weaker: 44% PP-NRS4 at Week 12 versus 75% for pooled placebo, though skin endpoints improved (44% EASI-75 vs 13% placebo). Safety was clean, with no patient discontinuations and ADA incidence of 7.8%. Two Phase 2 trials, ATTUNE-CPUO (~300 patients) and ATTUNE-AD (~255 patients), are slated to start in the first half of 2027.
At the time of this announcement, ATTO was trading at $14.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $684.8M. The 52-week trading range was $12.94 to $28.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.